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Introduction
   In the United States and Europe alone, 100.000 patients receive 
surgery due to peripheral nerve injury, causing 150.000 billion dollars 
in estimated costs, of which 87% represent lost productivity [1-2]. 
Peripheral nerve injury leads to two debilitating situations: 1) 
neuropathic pain and 2) alterations in motor control; autonomic 
symptoms can also be present when autonomic nerves are injured 
(https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/
Fact-Sheets/Peripheral-Neuropathy-Fact-Sheet). Typical manifestations 
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of neuropathic pain are allodynia (painful sensations in humans or 
pain-like behavior in animals, elicited by a mechanical or thermal 
stimulus that normally does not cause pain) and hyperalgesia (an 
increased pain response produced by a stimulus that normally causes 
pain in humans or pain-like behavior in animals) [3]. Motor control 
of striated muscles is also severely compromised during peripheral 
nerve injury, with recovery being highly dependent both in the 
efficiency as well as the speed at which regeneration of the injured 
nerves occurs [1]. The mechanistic analysis of peripheral nerve 
injury, regeneration and neuropathic pain in humans is of high 
complexity. However, several animal models have been developed 
(see [4]) in order to expand our knowledge about the molecular and 
cellular mechanisms underlying the mentioned conditions and to 
develop potential new pharmacological therapies (see [1, 5]).
Wallerian degeneration during peripheral nerve injury
    The basic structure of peripheral nerves includes two main 
components: axons and Schwann cells (SC), the latter involved in the 
synthesis of the myelin sheet surrounding myelinated nerves [6]. 
Mechanical injury of peripheral nerves, for example, due to axotomy 
or intense compression, commonly leads to nerve degeneration, first
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Abstract 
Traumatic injury of peripheral nerves is a serious concern for both patients and clinicians, and is commonly associated to neuropathic 
pain and complete or partial loss of functionality of the affected limb. Stem cell therapy has emerged as a promising tool to improve 
the outcome of patients with peripheral nerve injury, and an increasing number of pre-clinical and clinical studies are adding support 
towards their use in humans. In the present review, we will address specifically the participation of bone marrow stromal cells (BMSC; 
including a group of multipotent adult progenitor cells (MAP)) and bone marrow mononuclear cells (BMMC, a heterogeneous 
fraction that contains BMSC populations, among others), both of endogenous origin or exogenously transplanted, for the control of 
pain and the improvement of regeneration. We will describe the state-of-the-art knowledge on the cellular and molecular 
mechanisms involved in the action of BMSC and BMMC during traumatic injury of nerves. Finally, we will address the translational 
implications that may eventually lead to therapeutic options for humans.
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line in certain clinical circumstances). The drugs that could be used as 
a third line treatment include botulinum toxin A and strong opioids 
[30-32].
       Despite the existence of such grading methods, neuropathic pain 
treatment is complex; it is estimated that only 50% of affected pati-
ents respond with partial relief [33]. Exacerbating the situation, the 
majority of the analgesics currently prescribed cause some type of 
adverse effect, limiting their use in high doses or for long periods of 
time [34].
     Finally, there is currently no clinically available pharmacologic 
approach that can efficiently restore damaged nerves, even though a 
number of molecules including peptides, growth factors, hormones 
and immune suppressants are being studied at the preclinical level 
(see [1, 35]).
Interventionist strategies
        There are some conditions under which pain becomes refractory 
and no longer responds to treatment. For this type of patients, other 
kinds of therapies are applied: epidural blockade with local analgesics 
and steroids, sympathetic blockade, or radiofrequency treatment for 
herpes zoster or spinal radiculopathies [36-37]. The intrathecal 
administration of drugs can be useful for the refractory pain hand-
ling, optimizing patient’s functionality and minimizing the use of 
systemic drugs [38]. Currently, morphine and ziconotide are the two 
most widely used drugs for intrathecal, long-term administration, 
approved by the Food and Drug Administration (FDA).
     Concerning nerve repair, a direct intervention using epineural 
micro-sutures is the surgical treatment of choice, but only in conditi-
ons of tension-free coaptation and good vascularization. Otherwise, 
nerve grafts are used to account for significant gaps between the 
proximal and distal nerve stumps. Alternatively, nerve transfers (use 
of a healthy nerve to reconnect the distal stump of a relevant 
damaged nerve) or nerve conduits (use of biological or synthetic 
nerve guidance channels), sometimes with luminal additives (e.g. 
neurotrophic factors) can be used in a select number of clinical 
situations. However, the challenge remains, as in many cases, patients 
treated as described above show only partial recovery (see [1, 39]). 
Finally, a number of experimental strategies including the so-called 
electroceuticals (delivery of electrical impulses), fat grafting and 
optogenetics are being intensely evaluated using animal models [2].
Cell therapy strategies
    Transplant of diverse types of cells for the improvement of 
functional and morphological recovery of damaged nerves is one of 
the most recent developments in search of options for pain treatment 
and regeneration [1]. In the following sections, these approaches will 
be addressed in detail, particularly concerning peripheral nerve 
injury, and the evolution of the concept of cell transplantation of 
different types of cells.
The use of cultured Schwann cells for the repair of damaged 
peripheral nerves
       It is known that the central nervous system (CNS) has restricted 
possibilities for self-healing [40]. Even though neural stem cells are 
present in the adult, their ability to generate new functional neurons 
in response to neural damage is limited [40]. In contrast and as pre-
viously mentioned, axonal regeneration does occur in the peripheral 
nervous system (PNS), in great part thanks to the occurrence of WD 
and the accompanying proliferation and activation of SC [9-10]. In
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at the injured site and later also distally. Such degenerative event is 
typically called Wallerian degeneration (WD), a pathophysiological 
process characterized by loss of contact between the axon and the SC, 
as well as degeneration of the damaged nerve fibres. In the presence of 
a transient injury (acute nerve compression), the process above is 
followed by SC proliferation, demyelination, and subsequent axonal 
regeneration and remyelination [7-10].
      WD typically results in protein reorganization, with the appea-
rance of immunoreactive clustering of myelin basic protein (MBP) 
and P0 – two proteins characteristic of myelin - in the distal end of 
the damaged nerve [11-12]. WD also involves the dissolution of 
microtubules, rupture of neurofilament networks and changes in the 
phenotype of SC in myelinated axons. Interestingly, damaged SCs 
appear to differentiate into a pre-myelinating stage that allows them 
to proliferate once again [13]. These “activated” SC can also change 
their functional capacities, dissolving their myelin and behaving as 
phagocytes [13].
        The axonal destruction and removal of myelin during WD requ-
ires a full inflammatory response to be complete, which is reflected by 
the heavy invasion of macrophages within the bloodstream during the 
first 3-5 days after the injury [14-16]. This also leads to spontaneous 
migration of macrophages and non-differentiated cells from the bone 
marrow (CD34+) to proximal and distal portions of the damaged 
nerve, the later confirmed as bone marrow mononuclear cells 
(BMMC) by their expression of α-globin mRNA [12]. Macrophages 
participate in the remyelination process through phagocytic cleansing 
of myelin debris [17-18] as well as by release of trophic factors that 
influence nerve repair [19-21]. On the other hand, non-differentiated 
cells from bone marrow are believed to participate in the repair of 
injured nerves by, for example, differentiation into neuronal [22-25] 
or SCs [22].
        It is relevant to mention that the nerves affected by WD express 
a series of cytokines and chemokines, including interleukin (IL)-1β, 
IL-6, gamma interferon (IFNγ), tumoral necrotic factor alpha (TNF-
α), monocyte chemo attractant protein 1 alpha (MCP-1α) and the 
macrophage inflammatory protein 1 alpha (MIP-1α) [21, 26]. These 
molecules contribute to the coordination of inflammatory cellular 
traffic and axonal and myelin degradation, capable of acting as 
trophic factors for new axons. SCs from the distal stump also produce 
a great variety of neurotrophic factors and cytokines, adhesion 
molecules and extracellular proteins, also contributing to axonal 
regeneration [27-29].
Current strategies for the treatment of neuropathic pain and 
the improvement of nerve regeneration
Pharmacological strategies
      The Neuropathic Pain Special Interest Group (NeuPSIG) from 
the International Association for the Study of Pain (IASP) has issued 
guidelines based on clinical evidence for the pharmacological 
management of neuropathic pain, taking into account efficiency, 
adverse effects, life quality impact, convenience and costs involved. 
Thus, based on a lengthy analysis of tenths of clinical trials, the 
medications that are recommended in the mentioned guidelines as a 
first line treatment of neuropathic pain include tricyclic antidepressants 
(amitryptiline, imipramine, clomipramine), serotonin-noradrenaline 
reuptake inhibitors (duloxetine and venlafaxine), and calcium 
channel ligands α2-δ (eg. gabapentin and pregabalin). As second line 
treatment, tramadol, capsaicin and lidocaine patches are recomme-
nded (although opioid-based medication can also be used as the first
osteocytes and smooth muscle cells [58, 75]. MSC cannot only 
differentiate and dedifferentiate, but they can also transdifferentiate 
into cells types different from the mesenchymal lineage [57-58, 60]. So 
far, it has been demonstrated that they are capable of giving rise to 
cardiomyocytes [77], hepatocytes [78], neurons [79-80] and SC [24].
     HSC and MSC from bone marrow can be easily separated in 
culture, as HSC remain in the suspension while MSC adhere to the 
plastic used for cell culturing [58, 75]. The cells attached are also 
known as BMSC and include a population with high plasticity that 
give place to multipotent adult progenitors (MAPs), stromal progeni-
tors and mature stromal cells.
       Another relevant feature of BMSC is their ability to migrate and 
implant in the nervous system, as it has been demonstrated by the 
identification of labeled BMSC in the brain of irradiated mice receiving 
systemic infusion of such cells [81]. Moreover, it has been demonstrated 
that BMSC actively participate in regeneration processes of the central 
nervous system (CNS), promoting a functional recovery in animals 
with different types of neurological damage [82-89]. Interestingly, 
once BMSC are installed in the damaged brain, they begin to express 
neuronal (NeuN) and astrocytic markers (glial fibrilar acidic protein 
(GFAP)) [89]. Altogether, these characteristics of BMSC highlighted 
their potential for the development of strategies in tissue repair 
therapy, including the nervous system [58, 72, 74] [Table I].
BMMC
     BMMC, also obtained from bone marrow samples, comprise a 
heterogeneous cellular fraction including BMSC, HSC [90], hemato-
poietic precursors and endothelial cells [91]. This heterogeneity has 
led some authors to question the use of BMMC. However, it is well 
known that BMSC are susceptible to phenotypic rearrangements in 
culture, meaning that the populations obtained for different transpla-
nts are not necessarily homogenous [92]. In contrast, it has been 
proposed that there is a synergistic interaction between the stromal 
and non-stromal components of BMMC, which may optimize their 
regenerating capacity in damaged nerves [93]. Hence BMMC have 
recently become the focus of attention, not only for their easy 
production, but also because they do not require passage through 
culturing protocols for their expansion and/or differentiation, 
therefore bypassing phenotypical rearrangements that can occur 
when handling BMSC [92].
      BMMC promote angiogenesis, neuroprotection and neurorege-
neration as it was observed in various rodent models of CNS [94-96] 
and PNS injury [97]. Also, it has been demonstrated that BMMC 
differentiate into hepatocytes in animal models with hepatic damage 
[98], and that they can also differentiate into cardiomyocytes or 
contribute to the reduction of inflammation in the context of cardiac 
infarction [99-100]. Finally, BMMC produce numerous cytokines and 
trophic factors that delay cell death [101-102] and promote the 
recovery of several types of damaged tissue [91, 103-104] [Table I].
Influence of BMSC and BMMC on neuropathic pain 
        Coronel et al. [105] first showed that systemic injection of BMSC 
in rats with sciatic nerve crush results in a very clear mechanical and 
thermal antiallodynic effect. Moreover, they demonstrated that the 
effect was positive both in preventive and ameliorating fashions 
[105]. Importantly, the administration of vehicle or other population 
of marrow derived cells (hematopoietic mononuclear cells (MNC-H)) 
failed to exert the antiallodynic effects, indicating that the ability to 
attenuate pain was inherent of BMSC [105]. Further supporting their 
antiallodynic role, it was later shown that systemic injection of BMSC
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fact, Hall described that SC derived from the distal segment of a nerve 
damaged by axotomy or compression are essential for the myelination 
of regenerated axons [9].
The observations above led to the early proposal of SC transpla-
ntation for the treatment of damaged peripheral nerves. In fact, even 
though it has been observed that the PNS is able to self-regenerate 
when it is provided with an artificial graft composed of non-cellular 
substances like type I collagen or alginate [41-43], such capacity is 
enhanced by the additional presence of SC or SC-like cells (induced 
MSCs). In support, several studies have shown that SC transplantation 
delays cell death, prevents axonal degeneration [44-45], promotes 
remyelination and increases the conduction of action potentials 
through regenerated nerves [22-24, 46-49]. However, drawbacks in the 
application of such therapy in the clinical setting include: 1) the fact 
that, to obtain SC for autologous transplant, another healthy nerve 
should be sacrificed [50], 2) the low yields of SC isolation [50-52] and 
3) the need for significantly lengthy cell culture techniques to obtain
an optimal number of SC, making them less appealing in the context
of emergency due to trauma.
The emergence of stem cells for transplantation
The limitations in the use of SC for transplantation led to the 
search for and characterization of some other type of cell that, in 
addition to promoting remyelination, was multipotent and readily 
available, could proliferate in vitro, and could easily integrate into the 
receptor tissue [50-56]. With such objectives in mind, embryonic stem 
cells emerged as an interesting option, particularly because of their 
capacity to differentiate into a multiplicity of phenotypes, including 
neural ones [40, 50, 57-61]. However, the significant restrictions 
hindering the use of embryonic cells for transplantation in humans, 
which include ethical concerns, their viability, purity and carcinogenic 
potential, promoted the emergence of other sources of adult multipo-
tent cells that stimulated neural regeneration in different experimental 
models of nerve injury.
 The effort led to the identification of a number of adult multi-
potent cells such as bone marrow mesenchymal stem cells [62], 
olfactory ensheathing cells [63-64], endothelial precursors [65], adipo-
cyte mesenchymal stem cells [66-68], dental pulp stem cells [69], and 
skin-derived precursor stem cells [70]. Stem cells offer a multipotent 
cell source for the replacement of damaged or dead cells/neurons, and 
represent a pathway for the release of trophic factors to injured nerves 
and neurons [71]. Although the disadvantages and uncertainties 
regarding the application of pluri- or multipotent cells are still many, 
the possibilities and advantages offered by this type of treatment are 
truly fascinating: nothing more and nothing less than tissue repair [40, 
58, 61, 72-74].
Of the various stem cells studied thus far, two have gained 
attention in the last two decades, as suitable for performing autologous 
transplants: 1) Bone marrow stromal cells (BMSC) and 2) bone 
marrow mononuclear cells (BMMC).
Presenting BMSC and BMMC
BMSC
Two different populations of multipotent adult stem cells 
have been identified in bone marrow: hematopoietic (HSC) and 
mesenchymal (MSC) stem cells [58, 75]. MSC represent around 
0.001% of the total cells found in the bone marrow and are in charge 
of creating the adequate microenvironment for renewal, proliferation 
and differenti-ation of hematopoietic cells [75-76]. MSC give rise 
to stromal cells (fibroblasts, adipocytes and vascular endothelial 
cells), chondrocytes, 
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Table I: Comparison between BMSC and BMMC
after induction of sciatic nerve crush also show a more rapid 
recovery from allodynia, as compared to untreated rats (Brumovsky, 
Setton-Avruj, unpublished results). The difference between studies, 
with delayed antiallodynic effect described by Klass et al. [110] vs. 
the immediate effect observed by Usach et al. [113] when rats are 
treated with CMMO, remains to be clarified. However, each study 
addressed chronic (CCI) vs. acute neuropathy (sciatic nerve crush), 
respectively. It could be speculated that the severity of the injury 
had an influence on the efficacy and efficiency of effect of CMMO.
       Finally, the benefits derived from the use of BMSC and BMMC, 
and the potential mechanisms involved, have also been recently 
addressed in the context of several other pain-inducing conditions, 
including cancer [114].
Influence of BMSC and BMMC on peripheral nerve regene-
ration 
       In the first studies addressing the beneficial role of transplanted 
undifferentiated BMSC in the regeneration of damaged peripheral 
nerves, Cuevas et al. [23, 115] showed that rats receiving an injection 
of BMSC in the distal stump of the transected sciatic nerve had signi-
ficant improvements on the walking track test, along with complete 
and uniform re-connection between the proximal and distal stumps, 
as shown from day 33 after injury. Moreover, the authors also showed 
that the effect was long-lasting (improved locomotion up to 180 days 
after injury) [23], and depended on the homing (migration) of BMSC 
at the site of injury [115].
    In agreement with the initial studies described above, it was 
observed in rats with full sciatic nerve transection and a 15 mm gap, 
that the use of a silicone tube containing BMSC suspended in gelatin 
and various supporting substances results in improved walking 
behavior, reduced loss of gastrocnemius muscle weight and  electro-
myography magnitude, and a greater number of regenerating axons 
and elevated neurofilament and MBP protein levels within the tube 
[116]. Importantly, the authors also showed elevated expression of 
various neurotrophic factors within the tubes, including NGF, BDNF 
and GDNF, at both early and late phases of transplantation [116]. 
Similar outcomes were observed using BMSC-loaded epineural tubes 
[117], inside-out vein [118] or artery conduits [119] and chitosan 
conduits [120-121], as well as the combination of BMSC and 
experimental axonal regeneration promoters such as chondroitinase 
ABC (see [122-123]).
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in rats with chronic infraorbital nerve compression or ligation of the 
tendon of the anterior superficial part of the masseter muscle results 
in long-term attenuation of mechanical hypersensitivity and allodynia 
[106]. Moreover, systemic injection of human BMSC in mice with a 
selective injury of the tibial and common peroneal branches of the 
sciatic nerve (also called spared nerve injury or SNI) has been shown 
to reduce thermal and mechanical allodynia [107].
    Local application of BMSC has also been shown effective in 
modulating neuropathic pain. Thus, intra-ganglionar administration 
of BMSC in rats with single ligature nerve constriction, results in a 
clear antiallodynic effect [108]. Also, both ipsilateral intramuscular 
[106] and intrathecal administration [109] of BMSC in rats with
ligation of the masseter muscle tendon [106] or mice with chronic
constriction injury (CCI) or SNI of the sciatic nerve [109], results in a
prolonged decrease in mechanical and thermal hypersensitivity.
Interestingly, the intrathecal effects of BMSC were long-lasting
(several weeks) and equally efficient whether administered in the early 
or late stages of nerve injury-induced neuropathic pain [109].
 BMMC also exhibit an antiallodynic and antihyperalgesic profile, 
as shown in different models of neuropathic pain. The first study 
suggesting an effect on pain was published by Klass et al. [110] in rats 
undergoing CCI. The authors found that intravenous injection of 
BMMC on the same day of injury reversed mechanical allodynia and 
thermal hyperalgesia in rats with persistent neuropathic pain, 10 days 
after injury [110]. The effect was not immediate, which suggested that 
BMMC treatment does not prevent neuropathic pain [110]. This study 
was followed by another one where the unilateral injection of BMMC 
in the skeletal muscle of the hindpaw was practised in rats with 
diabetic neuropathy [111]. In these rats, BMMC treatment resulted in 
a reduction of mechanical and cold hyperalgesia, and improvements 
in vascular flow, conduction velocities of sensory and motor nerves in 
the treated limb [111]. Interestingly, it seems that this effect may be 
dependent on the age and health of the donor, since the use of BMMC 
from old or diabetic rats exhibits impaired therapeutic effects [112].
The most recent published study in rats shows that systemic 
transplantation of BMMC on the same day of sciatic nerve 
crushing completely prevents mechanical allodynia [113], in contrast 
to the observations by Klass et al. [110] described above; in fact, 
BMMC-treated rats remained pain-free throughout the assessed 
period compared to untreated rats [113]. Furthermore, this effect 
seems not only to be preventive, as rats treated with BMMC 7 days 
Vanina U, Florencia, Mariana M, Gonzalo P, Candelaria L, Mailín C, Marcelo V, Patricia SA, Pablo B. Bone Marrow-Derived Cells and Peripheral Nerve 
Injury-Translational Implications for Pain and Regeneration Treatments Clin Pharmacol Transl Med. 2018; 2(2): 112-124.
   BMMC have also emerged as an interesting option for the 
treatment of damaged nerves. Thus, it has been shown that BMMC 
transplanted directly between the proximal and distal ends of the 
axotomized sciatic nerve in rats, facilitates myelin formation and 
axonal regeneration of the injured nerve [97, 124-128]. Furthermore, a 
reduction in neuronal cell death and enhanced axonal outgrowth in 
the DRG neurons in vitro of rats treated with BMMC was also obse-
rved [97]. More recently, the beneficial effect of BMMC on peripheral 
nerve regeneration has been addressed in rats with sciatic nerve 
crush, and after intravascular administration of the experimental cells 
[113, 129]. Here, the pro-regenerative effect began within a week of 
treatment with intravascular BMMC, with treated rats showing clear 
signs of axonal recovery and untreated rats maintaining the typical 
WD alterations, with presence of large numbers of residual myelin 
and axons. Only by day 21, improvements were also evident in 
untreated rats, although never reaching the level of improvement 
observed in BMMC-treated animals [113, 129].
Mechanisms of action of BMSC and BMMC in their role as 
modulators of neuropathic pain and peripheral nerve 
regeneration
Migration and implantation
      One of the earliest hypotheses to explain the mode of action of 
BMSC after their administration in animals with peripheral nerve 
injury suggested that these cells migrate towards damaged tissues. 
This was shown in rats with single ligature nerve  constriction, where 
BMSC transplanted directly into the L4 dorsal root ganglion (DRG) 
of the injured rats resulted in prevention of mechanical and thermal 
allodynia, accompanied by migration and colonization of other 
ipsilateral (but not the contralateral) ganglia affected by the injury 
(L3, L5 and L6) [Figure 1], and modification of the expression levels of 
neuropeptides and other neuromodulators [108, 130-131]. More 
recently, it has been observed that intrathecal administration of 
BMSC in rats with CCI or SNI results in migration of these cells 
towards injured DRGs, as early as 3 days after treatment and with 
clear, long-term consequences in pain-like behavior [109].
     The observation of a migratory behavior for BMSC led to the 
question of what type of chemoattractants dictate the migration of 
BMSC towards damaged tissue. Monocyte chemoattractant protein-1α 
(MCP-1α) and stromal cell-derived factor-1 (SDF-1; derived from the 
CXCL12 gene) are two chemoattractants shown to participate in the 
migration of BMSC, both in vitro and in vivo [132-134]. Interestingly, 
crushing of the sciatic nerve induces the expression of MCP-1α and 
SDF-1 in small and medium DRG neurons, and glial cells, respectively 
(Coronel, personal communication), and of SDF-1 in SC present in the 
distal end of the injured nerve [135]. Moreover, an increase in 
ganglionar immunoreactivity for MCP-1α has been described after 
direct compression of a spinal ganglion [136]. Importantly, BMSC 
express the surface proteins CXCR4 and CCR2, acting as SDF-1 and 
MCP-1α receptors, respectively [134]. More recently, the BMSC 
chemoattractant role of SDF-1 was further confirmed in mice with 
CCI or SNI receiving intrathecal BMSC [109]. In these mice, upregu-
lated levels of SDF-1 were observed in ipsilateral L4-6 DRGs, and in 
vitro analysis showed that SDF-1 induces mouse BMSC migration, 
whereas the use of a CXCR4 antagonist blocked such behavior [109]. 
Moreover, intrathecal administration of CXCR4 siRNA-treated BMSC 
in injured mice showed a progressive compromise of the BMSC-
dependent antiallodynic effect, along with a reduction in the number 
of BMSC present in the ipsilateral L4-6 DRGs [109].  
   Other chemoattractant molecules potentially involved in BMSC 
migration and nesting in injured tissues are various adhesion mole-
cules such as transient axonal glycoprotein 1 [137], gicerine [138] and 
N-cadherin [139], all showing altered ganglionar expression after a
peripheral nerve injury. Similarly, expression of adhesion molecules
such as NCAM and L1-CAM is regulated by changes in the electro-
physiology of neurons during sciatic nerve injury [139]. In summary,
tissue injury appears to create a microenvironment that allows the
recruitment and implantation of circulating BMSC in the injured
ganglia, and possibly also nerves (see below).
 In contrast to BMSC, migration and implantation of BMMC has 
been addressed so far in the context of the damaged nerves. In 
particular, it has been reported that cells lacking typical SC morphology 
and expressing the multipotent markers CD34, CD90 and CD105 are 
present in the crush site and distal end of the injured nerves within 
the first 5 days after injury, which suggests the arrival of endogenous 
[129] or transplanted BMMC [113, 129]. These findings also reinfo-
rce the concept of an endogenous repair mechanism consisting of
BMMC recruitment triggered by peripheral nerve injury. However,
the mechanisms involved remain to be established, as well as whether
BMMC also migrate and nest in DRGs or spinal cord areas affected
by peripheral nerve injury.
Transdifferentiation
 Once implanted in mouse DRGs, BMSC have been shown to 
survive for prolonged periods of time (only showing a sharp decrease 
70 days after administration) [109]. Such a long survival entertained 
the idea of transdifferentiation within DRGs, especially after reports 
showing that transplanted BMSC in the CNS begin to express 
neuronal and astrocytic markers [57, 89]. However, in rats with single 
ligature nerve constriction and intraganglionar administration of 
BMSC, no signs of transdifferentiation were found, as shown by the 
lack of expression of neural or glial markers in the implanted cells 
(Coronel, personal communication). More recently, presence of 
many CD90-positives BMSC has been shown 28 days after intrathecal 
administration. However, no signs of trans differentiation into 
neurons, glia or monocyites was obtained [109]. While more research 
is needed to completely rule out processes of BMSC  transdifferentia-
tion within DRGs, it seems that, at least in mice with peripheral 
neuropathy, the positive effects on pain behavior did not depend on 
the differentiation of BMSC but on their interaction with neurons 
and possibly also glial cells (see below).
        In contrast, the pro-regenerative role of BMSC on damaged axons 
of animals with peripheral nerve injury appears to depend, at least in 
part on transdifferentiation. Studies in vitro have shown that BMSC 
differentiate into cells with morphology and phenotype characteristic 
of SC, as shown by their expression of neurotrophin factor p75 
(p75NTR), S100, O4 and GFAP [115, 140-141]. Tohill and Terenghi 
[49] observed that treatment of bone marrow MSC with the SC
mitogen glial growth factor induces the synthesis of GFAP and S100β,
and results in the identification of a small population of SC-like cells
among cells treated as such. In support, in vivo studies in rat by
Dezawa et al. [22] and Mimura et al. [24] showed that these BMSC-
derived SC transplanted into artificial grafts used to reconnect
completely severed sciatic nerves maintain their SC phenotype (as
shown by their expression of mature SC markers) [24], promote
myelination and neural regeneration, and facilitate the reconnection
between the proximal and distal ends of the injured nerve within the
first 6 months after injury [24]. Importantly, animals receiving such
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Figure 1: Possible therapeutic implications of BMSC and BMMC transplant for the treatment of peripheral nerve injury. The results 
presented in this review demonstrate that the intraganglionic, intraneural or intravascular transplant of BMSC or BMMC results in their 
migration and specific recruitment by injured areas, partly due to chemotactic factor secretion. The migration and nesting of BMSC and 
BMMC after injury results in various proposed biological effects: a) transdifferentiation to Schwann cells or neurons, b) paracrine actions with 
the release of neurotrophic factors, among others, and c) the modulation of host cell chemical phenotype, altering protein expression in DRGs, 
nerves and the spinal cord. Bone marrow cell therapeutic potential is high, with effects on neuropathic pain, axonal regeneration and nerve 
function as the most prominent. All this evidence suggests that transplantation of BMSC and BMMC, especially through the systemic route, 
could be considered an attractive therapeutic strategy in the treatment of patients with acute or chronic pain.
transplant showed a significant improvement in motor behavior and 
in nerve electrophysiological properties, as compared to control 
groups [24]. Finally, intraneural administration of undifferentiated 
BMSC in the distal stump of the axotomized rat sciatic nerve results 
in their migration and integration [23], as well as in the acceleration 
of motor recovery [23, 115-116, 142]. Moreover, such physiological 
effects may also be dependent on transdifferentiation, as suggested by 
the observation that even undifferentiated BMSC transplanted into 
an artificial conduit to repair severed sciatic nerves in the rat are 
found to express S100β [48, 142].
      BMMC also appear to undergo transdifferentiation after nesting 
in injured peripheral nerves. BMMC contain an enriched population 
of lymphocytes, monocytes, hematopoietic progenitor cells, endothelial
progenitor cells and BMSC. Prior transplantation, BMMC phenotype 
analysis shows a small proportion of CD34+ and CD105+ cells as well 
as a high proportion of CD90+ cells compatible with the presence of 
multipotent cells [113, 143]. However, once nested, some of these 
cells, labelled using the fluorophore 5-(and 6)-(((4-chloromethyl) 
benzoyl) amino) tetramethylrhodamine (CMTMR), are observed to 
express SC markers S100β and MBP, both distally and in the injured 
area [129]. Moreover, further studies using the transgenic strain 
Wistar-TgN(CAG-GFP)184ys have shown morphological changes in 
transplanted cells from round-shaped to spindle-shaped, together 
with the expression of SC markers [143]. Finally, some cells also 
express the neural marker PGP 9.5 and exhibit small size, round shape 
and two nuclei [129].
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Paracrine actions
   Regardless of their phenotypic fate (transdifferentiation vs non-
transdifferentiation), it is becoming clear that implanted BMSC or 
BMMC exert their effects by means of paracrine actions. In 
agreement, neuroimmunomodulation has recently been proposed 
as a relevant mechanism to explain the pro-regenerative role of 
BMSC [113, 144-145]. With such hypothesis in mind, nested 
BMSC and BMMC could functionally be thought as glia-like cells, 
synthesizing and releasing trophic factors to promote the survival 
of damaged sensory neurons and axons. In fact, BMSC constituti-
vely secrete a broad spectrum of cytokines, growth factors and 
chemokines, and express chemokine receptors [116-117, 122-123, 
134, 146-148] that, in their natural environment, the bone marrow, 
modulate the survival, proliferation and differentiation of HSC 
and their progeny [146, 149]. In support, an increase in the 
production of nerve and brain-derived nerve growth factors (NGF 
and BDNF, respectively), with parallel functional recovery, has 
been demonstrated following the administration of BMSC to 
animals with brain injury [87] or spinal cord trauma [84]. 
Accordingly, NGF, BDNF and vascular endothelial growth factor 
(VEGF) expressions have been detected in transplanted BMSC in 
rats with sciatic nerve axotomy [117, 122-123], which appears to 
contribute to the higher content of such and other growth factors 
in the regenerated tissue [116].
    NGF [150-151] acts through the activation of the low affinity 
receptor p75NTR [152], and the high affinity receptor TrkA [153], 
both expressed in primary afferent neurons [154]. Interestingly, an 
increase has been observed in the levels of the active phospho-
rylated form of the TrkA receptor in the DRGs of animals with 
single ligature nerve constriction and intraganglionic injection of 
BMSC (Coronel, personal communication), suggesting a greater 
activity of the NGF signaling pathway. It remains to be established 
whether the potentially higher NGF activity is due to secretion 
from BMSC, or from satellite ganglion cells within DRGs.
     The quick onset of antinociceptive actions of BMSC nested within 
the lumbar spinal cord [107, 109], lumbar DRGs [109, 130] and the 
prefrontal cortex [107] after systemic [107], intraganglionic [109, 130] 
or intrathecal [109] administration further supports the hypothesis of 
paracrine actions [107-109, 130]. In fact, after their intrathecal 
administration and homing in the spinal cord and DRGs, BMSC 
synthesize and secrete large amounts of transforming growth factor 
beta 1 (TGF-β1), an anti-inflammatory cytokine per excellence. Such 
BMSC-dependent secretion of TGF-β1 appears to modulate pain-like 
behavior in rats with CCI, since its blockade using antibodies or small 
interfering RNA resulted in neutralization of the antiallodynic and 
antihyperalgesic effects of intrathecal BMSCs [109]. Furthermore, the 
exogenous administration of TGF-β1 in rats with CCI potently 
inhibited neuropathic pain [109]. In contrast, the release of the anti-
inflammatory interleukin 10 (IL-10) from BMSCs was very low, and 
did not seem to contribute to the BMSC-induced pain relief, as shown 
by the lack of effect of IL-10 neutralization on the pain relief induced 
by intrathecal BMSCs [109]. All these observations are in agreement 
with a number of known actions for TGF-β1, including: 1) a 
reduction in the activation and proliferation of spinal and ganglionar 
microglia, 2) the suppression of the excitatory synaptic transmission 
in neurons of the outer lamina II of the spinal cord, and 3) a 
reduction in the frequency of neuronal action potentials of the DRGs 
(see [109]). Finally, the anti-inflammatory actions exposed thus far 
for BMSCs appear to also include the change from a pro-inflammatory 
to an anti-inflammatory state of macrophages and a reduction in 
the presence of pro-inflammatory interleukins (IL), as well as the 
induction of synthesis and secretion of the anti-inflammatory 
cytokine IL-10 [107, 155]. Moreover, it has even been suggested that 
the effect of BMSC on neuropathic pain involves the endogenous 
peripheral and central opioid system [106].
    Similar paracrine actions could also be attributed to BMMC, 
although this remains to be established. Interestingly, it has been 
suggested that the heterogeneity of cellular types included in the 
mononuclear fraction of the bone marrow could offer additional 
advantages, as synergistic interactions between the different cell types 
could potentiate paracrine actions and their pro-regenerative and 
antinociceptive actions [93]. Mechanistically, the non-stromal 
population may be thought as a source of cytokines and growth 
factors, contributing to the enhancement of survival and proliferation 
of the stromal fraction [156]. In support, increased expression of 
BDNF and glial derived neurotrophic factor has been shown in the 
injured sciatic nerves of rats treated with BMMC [127]. Likewise, 
BMMC treatment in rats undergoing diabetic neuropathy showed 
increased levels of VEGF, fibroblast growth factor and insulin-like 
growth factor in the treated nerves [157]. Such higher expression of 
trophic factors seems to be functional, as suggested in a study in rats 
with complete nerve transection, where co-administration of 
neutralizing antibodies for NGF (but not BDNF) with BMMC 
resulted in reduced neurite growth of sensory and sympathetic 
neurons maintained in vitro [97]. 
Modulation of host cell phenotype
     BMSC and BMMC modulation of pain and nerve regeneration 
after their migration, nesting, and chemical interaction within the 
injured tissue has been described in detail in the sections above. 
However, what type of influence do these cells have on the target 
tissue that alters the evolution of pain and regeneration?
       One answer to this broad question appears to be changes in the 
neurochemical phenotype of local neurons/cells in the vicinity of the 
implanted cells. This is supported by a study where intraganglionic 
BMSC were shown to partially prevent the upregulation of the 
expression of the neuropeptide tyrosine (NPY) and galanin (GAL) in 
DRG neurons in rats with peripheral nerve injury [130]. Likewise, 
intraganglionic BMSC prevented the decrease in the number of NPY 
Y1R-positive neurons [130]. It is known that NPY and GAL are 
actively involved in the modulation of nociception, with anti- and 
pronociceptive actions being attributed to both peptides [158-165]. 
Such disparity in their actions is related to the ability of these peptides 
to bind to different subtypes of associated receptors [166-167]. As for 
NPY, there is evidence to suggest that Y1R is predominantly antino-
ciceptive [164-165, 168-169], whereas Y2R would mediate 
NPY proalgesic actions [163-164]. Conserved levels of Y1R in 
primary afferent neurons in rats treated with BMSC presuppose the 
mainte-nance of its transport to the primary afferent terminals of 
the spinal cord, where its activation has been shown to reduce 
intraspinal secretion of excitatory neuropeptides such as substance 
P [170-171]. In addition, maintained Y1R expression at the cell 
body level, plus some degree of NPY expression in DRG neurons of 
rats with periphe-ral nerve injury treated with BMSC could facilitate 
the occurrence of a phenomenon of intraganglionar "cross-
signaling" among different neuronal populations, facilitating the 
NPY-dependent inhibition of Y1R-positive nociceptors. Altogether, 
the persistence of Y1R at the ganglion and spinal levels in rats with 
peripheral neuropathy treated with BMSC could be one mechanism 
participating in the alleviation of pain.
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        The analysis described for the NPYergic system cannot be done in 
relation to GAL, since there is a lack of reliable antibodies for the 
detection of its receptor GalR1, clearly associated with the inhibitory 
effects of the peptide [159]. However, as with Y1R, sciatic nerve injury 
has been shown to induce a decrease in mRNA expression of both 
GalR1 and GalR2 in primary afferent neurons [172-174]. If BMSC had 
the same preventive effect on GalR1 as observed with Y1R, then the 
persistence of GAL expression in the injured ganglia of BMSC treated 
rats could also participate in intraganglionar "cross-signaling" and 
spinal inhibition of pain.
     Finally, it has also been shown that combined BMSC transpla-
ntation and chondroitinase ABC therapy in a model of acellular nerve 
allograft repair of the sciatic nerve in rats results in increased 
expression of NGF, BDNF and VEGF in the regenerated nerve [123]. 
Interestingly, it has also been shown that expression of these factors is 
also upregulated, and positively influences growth, in distal tissues 
such as target muscles and the spinal cord [123]. As mentioned in the 
previous section, it is very likely that these and other factors had 
BMSC and BMMC as sources [116-117, 122-123, 134, 146-148]. 
However, an additional possibility is that BMSC and BMMC 
promoted the synthesis and release of different trophic factors by local 
injured and distant associated tissues.
Modulation of the nerve degeneration-regeneration process
    After sciatic nerve crush, neutrophils initiate infiltration of the 
distal area (within 8 h after injury), although their presence is short-
lived [175]. Over the first days, monocytes are recruited to complete 
the degeneration process [176]. Considering the BMMC composition 
[113] and their regenerating ability after WD, the small amount of
remaining transplanted granulocytes may be speculated to leave the
injured area within the first hours, together with endogenous ones,
which might confirm the key role of the mononuclear fraction in the
beneficial effects observed on sciatic nerve regeneration.
 Therefore, BMMC may collaborate in the removal of myelin debris 
generated by a neuropathic lesion during demyelination, as an 
essential step to foster remyelination [113, 127, 129]. Importantly, the 
faster recovery of myelin sheath and damaged nerves in these animals 
translates into significant improvement in motor behavior and in 
nerve electrophysiological properties [24, 113, 129].
Translational implications
 The lack of effective and well-tolerated therapies for the treatment 
of neuropathic pain [30-31, 177], and the almost complete lack of 
effective methods to allow satisfactory regeneration of damaged 
peripheral nerves, stresses the need for the development of new 
therapeutic options. As described throughout this review, the concept 
of cell therapy using stem cells has gained considerable momentum, 
attracting the attention of the international scientific and medical 
community [178-180].
 Thinking with a translational perspective, BMSC and BMMC 
transplantation emerges as an interesting strategy. When focusing on 
BMSC, these are easy cells to isolate from the bone marrow and to 
purify, because of their typical adherence to plastic and the propensity 
to expand in culture [59]. Moreover, the use of BMSC avoids ethical 
and immunological concerns otherwise associated with the use of 
mesenchymal cells of embryonic origin. Finally, BMSC produce a 
large variety of cytokines and growth factors, either in vitro or in vivo 
[87, 147-148], which promote mechanisms of endogenous repair of 
injured tissues [87], further contributing to functional recovery [89].
       Intraganglionic administration of BMSC in the preclinical setting 
has been considerably useful to expose some of the potential mecha-
nisms behind the antinociceptive effects of this type of cells in rodent 
models of chronic pain [108, 130-131]. However, one important 
limitation of this experimental model is its route of administration; 
intraganglionic injection is technically complex, and could hardly be 
used in patients. Alternatively, the use of the intrathecal space for the 
administration of BMSC appears as a perfectly valid approach, 
especially in patients refractory to pharmacological treatment and 
already implanted with an intrathecal catheter [109]. Systemic 
transplantation of BMSC would certainly be a step forward in the 
search of a therapy less invasive for the treatment of chronic pain and 
the improvement of nerve regeneration, and several preclinical 
examples have been included in the present review (see previous 
sections). Importantly, BMSC are currently being addressed in the 
clinical setting, in trials assessing their effects in patients with lumbar 
disc degeneration [181] or knee osteoarthritis [182], after intradiscal 
or intraarticular administration, respectively. The results are promi-
sing, showing significant improvements in pain and disability 
assessments, and with favorable rates of safety and therapeutic 
feasibility [181-182].
        Despite the clear potential of BMSC as useful therapeutic agents, 
one of the most important limitations for their use is the ex vivo 
cellular manipulation required to obtain them [74]. Therapies based 
on the use of BMSC would require sampling through bone marrow 
puncture of the patient, isolation of BMSC and its expansion in 
culture. These procedures are expensive, laborious and do not always 
generate the optimum amount of cells. Moreover, phenotypical 
rearrangements have been reported in cultured BMSC [92]. Likewise, 
considering that many injuries that require regenerative techniques 
are the product of emergent situations such as car accidents, time 
becomes a determinant factor for which techniques depending on cell 
culture end up being ineffective. With such perspective, BMMC 
appear as an interesting alternative [113] and may be favored by three 
important aspects: 1) the immediate availability of cells for acute 
intervention, which would minimize potential malignant  transfo-
rmations [183] and phenotypic rearrangements [92] that exhibit 
BMSC throughout their culture passages, and would eventually allow 
autologous transplantation (only 60 minutes would be necessary for 
bone marrow isolation, obtaining BMMC and intravascular injection) 
[121, 184]; 2) intravascular BMMC transplantation is a minimally 
invasive procedure [185]; and 3) the spontaneous migration of the 
transplanted cells collaborates with the morphological and functional 
recovery. These three factors suggest that such an approach has the 
potential to avoid associated costs [184], and problems such as 
contamination and the need for infrastructure conditions for Good 
Manufacturing Practices [186]. 
      In previous sections, we have also presented several preclinical 
examples supporting the value of systemic BMMC transplantation as 
anti-allodynic and pro-regenerative agents, and comparable to those 
seen with systemic or intrathecal BMSC administration. Accordingly, 
BMMC transplantation is being addressed in clinical trials in patients 
with acute myocardial infarction (intramyocardial and intracoronary 
transplantation) [187-188] and with traumatic brain injury 
(intravenous transplant) [189], showing that BMMC treatment is 
feasible, safe, and results in improved cardiac function [187-188], as 
well as structural preservation of critical SNC architecture with 
downregulation of inflammatory biomarkers [189]. In addition, 
autologous BMMC injection in ischemic stroke patients has shed 
light on optimal cell doses, especially after intraarterial transplant [190]. 
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In these cases, cellular therapy is well-tolerated and opens new 
perspectives in the treatment of peripheral arterial diseases [190-191]. 
Moreover, clinical trials using intraspinal injection of autologous 
BMMC has proven to be feasible and safe in patients with amyotro-
phic lateral sclerosis, even if further assays are necessary to reach 
conclusive results [192]. While these studies show promise, more 
preclinical and clinical research will be required to establish the 
degree of benefit obtained from BMMC transplantation, for the 
treatment of neuropathic pain and peripheral nerve injury. The only 
available study thus far is by Braga-Silva et al. [193], where BMMC-
filled silicone tubes used to connect the ends of the median and ulnar 
nerves in human patients, showed better recovery than empty tubes.
Concluding remarks
   Topical or systemic transplantation of BMSC and BMMC in 
animals with peripheral nerve injury results in their migration and 
selective nesting in injured neural tissues (compressed nerves, DRGs, 
spinal cord). This is associated with a sharp reduction in pain mani-
festations, mitigation of the neurochemical changes usually observed 
in DRG neurons during peripheral nerve injury, and a faster 
degeneration-regeneration process, accompanied by improved 
electromyographic properties (Figure 1). Such beneficial effects are in 
agreement with similar observations made in various animal models 
of injury or disease of the nervous system, such as infarction [194], 
ischemia [86], cerebral trauma [89, 195], Parkinson's disease [196], 
contusion injury [83, 88, 197] and demyelinating processes of the 
spinal cord [57]. In these models, the successful migration and 
implantation in injured areas of intravascularly administered rat 
mesenchymal stem cells has also been associated to symptomatic 
recovery and regeneration.
      The effect on pain-like behavior of BMSC- and BMMC-treatment 
in injured animals is direct and immediate, and shows both the 
capacity to prevent or ameliorate pain. Also, BMMC transplantation 
reduces the time required to observe the onset of effective recovery of 
damaged nerves by at least 2 weeks, as compared to untreated rats. 
This improvement in recovery time is significant, considering that the 
gestation period of the rat is 21 days, a 70-day old rat is already 
considered adult, and its average life is 2 years.
     Based on the experimental studies described in this review, the 
hypothetical series of events associated with BMSC and BMMC 
transplant upon peripheral nerve lesion can be summarized as 
follows: 1) endogenous or transplanted BMSC or BMMC selectively 
migrate and nest within injured nerves/ganglia/spinal cord, presum-
ably due to the presence of a chemotactic environment, which may 
facilitate the arrival of the transplanted cells to altered tissues; 2) 
BMSC/BMMC exert an early immunomodulatory action through the 
synthesis and release of trophic factors and anti-inflammatory 
cytokines such as IL-10 [107] and TGF-β1 [109], among other 
molecules; 3) this leads to reduced activation and proliferation of 
microglia and astrocytes, suppressed excitatory synaptic transmission, 
and a lower frequency of action potential generation [107], among the 
few described effects thus far; 4) later, BMSC and BMMC transdiffe-
rentiate into neuronal and/or glial phenotypes, probably to replace 
damaged cells in the lesion area and potentially leading to long-term 
effects [143]; and 5) pain is reduced and nerve regeneration is 
enhanced as a consequence of all these changes. 
      Despite the points summarized above, much is still to be learnt 
about the exact mechanisms by which transplanted BMSC and 
BMMC modulate the activity of primary afferent neurons and injured 
nerves and favor immediate recovery from pain and latency-mediated 
morphological and functional regeneration [108, 113]. In addition, it 
also remains to be addressed if transplanted BMSC and BMMC could 
be useful in the treatment of other pain-associated conditions, such as 
inflammatory pain, visceral pain, and in gene-related pathologies 
such as Fabry's disease, with neuropathic pain as one salient symptom.
Acknoweldgement
We thank the Consejo Nacional de Investigaciones
Científicas y Técnicas (CONICET), the Ministry of Science, 
Technology and Productive Innovation, the University of Buenos 
Aires and Austral University, for continuous financial support of the 
research conducted in our laboratories on the topic of pluripotent cells 
for the treatment of pain and the improvement of nerve regeneration, 
and discussed accordingly in the present review.
References
Vanina U, Florencia, Mariana M, Gonzalo P, Candelaria L, Mailín C, Marcelo V, Patricia SA, Pablo B. Bone Marrow-Derived Cells and Peripheral Nerve 
Injury-Translational Implications for Pain and Regeneration Treatments Clin Pharmacol Transl Med. 2018; 2(2): 112-124.
Clin Pharmacol Transl Med, 2018 Volume 2(2): 121 - 124 
19. Miyauchi A, Kanje M, Danielsen N and Dahlin LB. Role of macrophages in the
stimulation and regeneration of sensory nerves by transposed granulation tissue and
temporal aspects of the response. Scand J Plast Reconstr Surg Hand Surg. 1997;
31:17-23. [Crossref] 
20. Dai ley AT, Avellino AM, Benthem L, Silver J and Kliot M. Complement depletion
reduces macrophage infiltration and activation during Wallerian degeneration and
axonal regeneration. J Neurosci. 1998; 18:6713-6722. [Crossref] 
21. Siebert H, Sachse A, Kuziel WA, Maeda N and Bruck W. The chemokine receptor
CCR2 is involved in macrophage recruitment to the injured peripheral nervous
system. J Neuroimmunol. 2000; 110:177-185. [Crossref] 
22. Dezawa M, Takahashi I, Esaki.M, Takano M and Sawada H. Sciatic nerve
regeneration in rats induced by transplantation of in vitro differentiated bone-marrow 
stromal cells. Eur J Neurosci. 2001; 14:1771-1776. [Crossref] 
23. Cuevas P, Carceller F, Garcia-Gomez I, Yan M and Dujovny M. Bone marrow stromal
cell implantation for peripheral nerve repair. Neurol Res. 2004; 26:230-232. [Crossref] 
24. Mimura T, Dezawa M, Kanno H, Sawada H and Yamamoto I. Peripheral nerve
regeneration by transplantation of bone marrow stromal cell-derived Schwann cells in
adult rats. J Neurosurg. 2004; 101:806-812. [Crossref] 
25. Zhang P, He X, Liu K, Zhao F, Fu Z, Zhang D, et al. Bone marrow stromal cells
differentiated into functional Schwann cells in injured rats sciatic nerve. Artif Cells
Blood Substit Immobil Biotechnol. 2004; 32:509-518. [Crossref] 
26. Cheepudomwit T, Guzelsu E, Zhou C, Griffin JW and Hoke A. Comparison of
cytokine expression profile during Wallerian degeneration of myelinated and
unmyelinated peripheral axons. Neurosci Lett. 2008; 430:230-235. [Crossref] 
27. Chernousov MA and Carey DJ. Schwann cell extracellular matrix molecules and their
receptors. Histol Histopathol. 2000; 15:593-601. [Crossref] 
28. Chernousov MA, Rothblum K, Tyler WA, Stahl RC and Carey DJ. Schwann cells
synthesize type V collagen that contains a novel alpha 4 chain. Molecular cloning,
biochemical characterization, and high affinity heparin binding of alpha 4(V) collagen. 
J Biol Chem. 2000; 275:28208-28215. [Crossref] 
29. Fu SY and Gordon T. The cellular and molecular basis of peripheral nerve
regeneration. Mol Neurobiol. 1997; 14:67-116. [Crossref] 
30. Finnerup NB and Attal N. Pharmacotherapy of neuropathic pain: time to rewrite the
rulebook? Pain Manag. 2016; 6:1-3. [Crossref] 
31. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al.
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta- 
analysis. Lancet Neurol. 2015; 14:162-173. [Crossref] 
32. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, et
al. Neuropathic pain: an updated grading system for research and clinical practice.
Pain. 2016; 157:1599-1606. [Crossref] 
33. Finnerup NB, Sindrup SH and Jensen TS. The evidence for pharmacological treatment 
of neuropathic pain. Pain. 2010; 150:573-581. [Crossref] 
34. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al.
Pharmacologic management of neuropathic pain: evidence-based recommendations.
Pain. 2007; 132:237-251. [Crossref] 
35. Chan KM, Gordon T, Zochodne DW and Power HA. Improving peripheral nerve
regeneration: from molecular mechanisms to potential therapeutic targets. Exp Neurol. 
2014; 261:826-835. [Crossref] 
36. Wong CS, Hui GK, Chung EK and Wong SH. Diagnosis and management of
neuropathic pain. Pain Manag. 2014; 4:221-231. [Crossref] 
37. Flores JC. Medicina del Dolor. 1st ed. 2014, España: Elsevier. [Crossref] 
38. Saulino M, Kim PS and Shaw E. Practical considerations and patient selection for
intrathecal drug delivery in the management of chronic pain. J Pain Res. 2014; 7:627- 
638. [Crossref] 
39. Zochodne DW. The challenges and beauty of peripheral nerve regrowth. J Peripher
Nerv Syst. 2012; 17:1-18. [Crossref] 
40. Zietlow R, Lane EL, Dunnett SB and Rosser AE. Human stem cells for CNS repair.
Cell Tissue Res. 2008; 331:301-322. [Crossref] 
41. Yoshii S, Oka M, Shima M, Taniguchi A, Taki Y, Akagi M, et al. Restoration of
function after spinal cord transection using a collagen bridge. J Biomed Mater Res A.
2004; 70:569-575. [Crossref]
42. Yoshii S, Shima M, Oka M, Taniguchi A, Taki Y, Akagi M, et al. Nerve regeneration
along collagen filament and the presence of distal nerve stump. Neurol Res. 2004;
26:145-150. [Crossref] 
43. Hashimoto T, Suzuki Y, Suzuki K, Nakashima T, Tanihara M, Ide C, et al. Review:
peripheral nerve regeneration using non-tubular alginate gel crosslinked with covalent 
bonds. J Mater Sci Mater Med. 2005; 16:503-509. [Crossref] 
44. Villegas-Perez MP, Vidal-Sanz M, Bray GM and Aguayo AJ. Influences of peripheral 
nerve grafts on the survival and regrowth of axotomized retinal ganglion cells in adult 
rats. J Neurosci. 1988; 8:265-280. [Crossref] 
45. Dezawa M, Kawana K and Adachi-Usami E. The role of Schwann cells during retinal
ganglion cell regeneration induced by peripheral nerve transplantation. Invest
Ophthalmol Vis Sci. 1997; 38:1401-1410. [Crossref] 
46. Feltri ML, Scherer SS, Wrabetz L, Kamholz J and Shy ME. Mitogen-expanded 
Schwann cells retain the capacity to myelinate regenerating axons after transplantation
into rat sciatic nerve. Proc Natl Acad Sci U S A. 1992; 89: 8827-8831. [Crossref] 
47. Honmou O, Felts PA, Waxman SG and Kocsis JD. Restoration of normal conduction
properties in demyelinated spinal cord axons in the adult rat by transplantation of
exogenous Schwann cells. J Neurosci. 1996; 16:3199-3208. [Crossref] 
48. Tohill M, Mantovani C, Wiberg M and Terenghi G. Rat bone marrow mesenchymal
stem cells express glial markers and stimulate nerve regeneration. Neurosci Lett. 2004; 
362:200-203. [Crossref] 
49. Tohill M, Terenghi G. Stem-cell plasticity and therapy for injuries of the peripheral
nervous system. Biotechnol Appl Biochem. 2004; 40:17-24. [Crossref] 
50. Kingham PJ, Kalbermatten DF, Mahay D, Armstrong SJ, Wiberg M, Terenghi G, et al. 
Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote
neurite outgrowth in vitro. Exp Neurol. 2007; 207: 267-274.[Crossref] 
51. Pluchino S and Martino G. The therapeutic use of stem cells for myelin repair in
autoimmune demyelinating disorders. J Neurol Sci. 2005; 233:117-119.[Crossref] 
52. Pluchino S, Zanotti L, Deleidi M and Martino G. Neural stem cells and their use as
therapeutic tool in neurological disorders. Brain Res Brain Res Rev. 2005; 48:211- 
219. [Crossref] 
53. Brustle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, et al.
Embryonic stem cell-derived glial precursors: a source of myelinating transplants. 
Science. 1999; 285:754-756. [Crossref] 
54. Akiyama Y, Radtke C, Honmou O and Kocsis JD. Remyelination of the spinal cord
following intravenous delivery of bone marrow cells. Glia. 2002; 39:229-236. 
[Crossref] 
55. Akiyama Y, Radtke C and Kocsis JD. Remyelination of the rat spinal cord by
transplantation of identified bone marrow stromal cells. J Neurosci. 2002; 22:6623- 
6630. [Crossref] 
56. Nistor GI, Totoiu MO, Haque N, Carpenter MK and Keirstead HS. Human embryonic
stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal
cord transplantation. Glia. 2005; 49:385-396. [Crossref] 
57. Bonilla S, Silva A, Valdes L, Geijo E, Garcia-Verdugo JM, Martinez S, et al.
Functional neural stem cells derived from adult bone marrow. Neuroscience. 2005;
133:85-95. [Crossref] 
58. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR,
et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature.
2002; 418:41-49. [Crossref] 
59. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science.
1997; 276:71-74. [Crossref] 
60. Blondheim NR, Levy YS, Ben-Zur T, Burshtein A, Cherlow T, Kan I, et al. Human
mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem 
Cells Dev. 2006; 15:141-164. [Crossref] 
61. Biernaskie J, Sparling JS, Liu J, Shannon CP, Plemel JR, Xie Y, et al. Skin-derived 
precursors generate myelinating Schwann cells that promote remyelination and
functional recovery after contusion spinal cord injury. J Neurosci. 2007; 27: 9545- 
9559. [Crossref] 
62. Cameron SH, Alwakeel AJ, Goddard L, Hobbs CE, Gowing EK, Barnett ER, et al.
Delayed post-treatment with bone marrow-derived mesenchymal stem cells is
neurorestorative of striatal medium-spiny projection neurons and improves motor
function after neonatal rat hypoxia-ischemia. Mol Cell Neurosci. 2015; 68:56-72. 
[Crossref] 
63. Guerout N, Duclos C, Drouot L, Abramovici O, Bon-Mardion N, Lacoume Y, et al.
Transplantation of olfactory ensheathing cells promotes axonal regeneration and
functional recovery of peripheral nerve lesion in rats. Muscle Nerve. 2011; 43:543- 
551. [Crossref] 
64. Guerout N, Paviot A, Bon-Mardion N, Duclos C, Genty D, Jean L, et al. Co- 
transplantation of olfactory ensheathing cells from mucosa and bulb origin enhances
functional recovery after peripheral nerve lesion. PLoS One. 2011; 6:e22816. 
[Crossref] 
65. Chen CW, Corselli M, Peault B and Huard J. Human blood-vessel-derived stem cells
for tissue repair and regeneration. J Biomed Biotechnol. 2012; 2012:597439. [Crossref] 
66. Gu JH, Ji YH, Dhong ES, Kim DH and Yoon ES. Transplantation of adipose derived
stem cells for peripheral nerve regeneration in sciatic nerve defects of the rat. Curr
Stem Cell Res Ther. 2012; 7:347-355. [Crossref] 
67. Hsueh YY, Chang YJ, Huang TC, Fan SC, Wang DH, Chen JJ, et al. Functional
recoveries of sciatic nerve regeneration by combining chitosan-coated conduit and
neurosphere cells induced from adipose-derived stem cells. Biomaterials. 2014;
35:2234-2244. [Crossref] 
Vanina U, Florencia, Mariana M, Gonzalo P, Candelaria L, Mailín C, Marcelo V, Patricia SA, Pablo B. Bone Marrow-Derived Cells and Peripheral Nerve 
Injury-Translational Implications for Pain and Regeneration Treatments Clin Pharmacol Transl Med. 2018; 2(2): 112-124.
Clin Pharmacol Transl Med, 2018 Volume 2(2): 122 - 124 
68. Plock JA, Schnider JT, Zhang W, Schweizer R, Tsuji W, Kostereva N, et al. Adipose- 
and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in
Vascularized Composite Allotransplantation. Transplantation. 2015; 99:1765-1773. 
[Crossref] 
69. Sakai K, Yamamoto A, Matsubara K, Nakamura S, Naruse M, Yamagata M, et al.
Human dental pulp-derived stem cells promote locomotor recovery after complete
transection of the rat spinal cord by multiple neuro-regenerative mechanisms. J Clin
Invest. 2012; 122:80-90. [Crossref] 
70. Walsh SK, Kumar R, Grochmal JK, Kemp SW, Forden J, Midha R, et al. Fate of stem 
cell transplants in peripheral nerves. Stem Cell Res. 2012; 8:226-238.[Crossref] 
71. Vadivelu S, Willsey M, Curry DJ and McDonald JW. Potential role of stem cells for
neuropathic pain disorders. Neurosurg Focus. 2013; 35: E11. [Crossref] 
72. Bianco P, Riminucci M, Gronthos S and Robey PG. Bone marrow stromal stem cells: 
nature, biology, and potential applications. Stem Cells. 2001; 19:180-192.[Crossref] 
73. Cova L, Ratti A, Volta M, Fogh I, Cardin V, Corbo M, et al. Stem cell therapy for
neurodegenerative diseases: the issue of transdifferentiation. Stem Cells Dev. 2004;
13:121-131. [Crossref] 
74. Mimeault M and Batra SK. Concise review: recent advances on the significance of
stem cells in tissue regeneration and cancer therapies. Stem Cells. 2006; 24:2319-2345. 
[Crossref] 
75. Short B, Brouard N, Occhiodoro-Scott T, Ramakrishnan A and Simmons PJ.
Mesenchymal stem cells. Arch Med Res. 2003; 34:565-571. [Crossref] 
76. Owen M. Marrow stromal stem cells. J Cell Sci Suppl. 1988; 10:63-76. [Crossref] 
77. Shim W and Wong P. Stem cell cardiomyoplasty: state-of-the-art. Ann Acad Med
Singapore. 2004; 33: 451-460. [Crossref] 
78. Shu SN, Wei L, Wang JH, Zhan YT, Chen HS, Wang Y, et al. Hepatic differentiation
capability of rat bone marrow-derived mesenchymal stem cells and hematopoietic stem 
cells. World J Gastroenterol. 2004; 10:2818-2822. [Crossref] 
79. Woodbury D, Schwarz EJ, Prockop DJ and Black IB. Adult rat and human bone
marrow stromal cells differentiate into neurons. J Neurosci Res. 2000; 61:364-370. 
[Crossref] 
80. Abouelfetouh A, Kondoh T, Ehara K and Kohmura E. Morphological differentiation of 
bone marrow stromal cells into neuron-like cells after co-culture with hippocampal
slice. Brain Res. 2004; 1029:114-119. [Crossref] 
81. Eglitis MA and Mezey E. Hematopoietic cells differentiate into both microglia and
macroglia in the brains of adult mice. Proc Natl Acad Sci USA. 1997; 94:4080-4085. 
[Crossref] 
82. Ohta M, Suzuki Y, Noda T, Kataoka K, Chou H, Ishikawa N, et al. Implantation of
neural stem cells via cerebrospinal fluid into the injured root. Neuroreport. 2004;
15:1249-1253. [Crossref] 
83. Zurita M, Vaquero J. Functional recovery in chronic paraplegia after bone marrow
stromal cells transplantation. Neuroreport. 2004; 15:1105-1108. [Crossref] 
84. Neuhuber B, Timothy Himes B, Shumsky JS, Gallo G and Fischer I. Axon growth and 
recovery of function supported by human bone marrow stromal cells in the injured
spinal cord exhibit donor variations. Brain Res. 2005; 1035:73-85. [Crossref] 
85. Lu J, Feron F, Ho SM, Mackay-Sim A and Waite PM. Transplantation of nasal
olfactory tissue promotes partial recovery in paraplegic adult rats. Brain Res. 2001;
889:344-357. [Crossref] 
86. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous 
administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke.
2001; 32:1005-1011. [Crossref] 
87. Mahmood A, Lu D and Chopp M. Intravenous administration of marrow stromal cells
(MSCs) increases the expression of growth factors in rat brain after traumatic brain
injury. J Neurotrauma. 2004; 21:33-39. [Crossref] 
88. Chopp M, Zhang XH, Li Y, Wang L, Chen J, Lu D, et al. Spinal cord injury in rat:
treatment with bone marrow stromal cell transplantation. Neuroreport. 2000; 11:3001- 
3005. [Crossref] 
89. Lu D, Mahmood A, Wang L, Li Y, Lu M, Chopp M, et al. Adult bone marrow stromal 
cells administered intravenously to rats after traumatic brain injury migrate into brain
and improve neurological outcome. Neuroreport. 2001; 12:559-563. [Crossref]
90. Weissman IL, Anderson DJ and Gage F. Stem and progenitor cells: origins,
phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol.
2001; 17:387-403. [Crossref] 
91. Wang QR, Wang BH, Huang YH, Dai G, Li WM, Yan Q, wt al. Purification and
growth of endothelial progenitor cells from murine bone marrow mononuclear cells. J
Cell Biochem. 2008; 103:21-29. [Crossref] 
92. Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, et al.
Isolation and characterization of bone marrow multipotential mesenchymal progenitor
cells. Arthritis Rheum. 2002; 46:3349-3360. [Crossref] 
93. Song F, Tang J, Geng R, Hu H, Zhu C, Cui W, et al. Comparison of the efficacy of
bone marrow mononuclear cells and bone mesenchymal stem cells in the treatment of
osteoarthritis in a sheep model. Int J Clin Exp Pathol. 2014; 7:1415-1426.[Crossref] 
94. Nakano-Doi A, Nakagomi T, Fujikawa M, Nakagomi N, Kubo S, Lu S, et al. Bone
marrow mononuclear cells promote proliferation of endogenous neural stem cells
through vascular niches after cerebral infarction. Stem Cells. 2010; 28:1292-1302. 
[Crossref] 
95. Pimentel-Coelho PM and Mendez-Otero R. Cell therapy for neonatal hypoxic- 
ischemic encephalopathy. Stem Cells Dev. 2010; 19:299-310. [Crossref] 
96. Zaverucha-do-Valle C, Gubert F, Bargas-Rega M, Coronel JL, Mesentier-Louro LA,
Mencalha A, et al. Bone marrow mononuclear cells increase retinal ganglion cell
survival and axon regeneration in the adult rat. Cell Transplant. 2011; 20:391-406. 
[Crossref] 
97. Ribeiro-Resende VT, Pimentel-Coelho PM, Mesentier-Louro LA, Mendez RM,
Mello-Silva JP, Cabral-da-Silva MC, et al. Trophic activity derived from bone marrow 
mononuclear cells increases peripheral nerve regeneration by acting on both neuronal
and glial cell populations. Neuroscience. 2009; 159:540-549. [Crossref] 
98. Kienstra KA, Jackson KA and Hirschi KK. Injury mechanism dictates contribution of
bone marrow-derived cells to murine hepatic vascular regeneration. Pediatr Res. 2008; 
63:131-136. [Crossref] 
99. Chen CH, Chang MY, Wang SS and Hsieh PC. Injection of autologous bone marrow
cells in hyaluronan hydrogel improves cardiac performance after infarction in pigs.
Am J Physiol Heart Circ Physiol. 2014; 306: H1078-1086. [Crossref] 
100. El-Mahdy N, Salem ML, El-Sayad M, El-Desouky KI and Zaghow N. Bone marrow
mononuclear cells enhance anti-inflammatory effects of pravastatin against
isoproterenol-induced myocardial infarction in rats. J Immunotoxicol. 2016; 13:393- 
402. [Crossref] 
101. Borlongan CV, Lind JG, Dillon-Carter O, Yu G, Hadman M, Cheng C, et al. Bone
marrow grafts restore cerebral blood flow and blood brain barrier in stroke rats. Brain
Res. 2004; 1010:108-116. [Crossref] 
102. Munoz JR, Stoutenger BR, Robinson AP, Spees JL and Prockop DJ. Human
stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural
stem cells in the hippocampus of mice. Proc Natl Acad Sci USA. 2005; 102:18171- 
18176. [Crossref] 
103. Kawamoto A and Losordo DW. Endothelial progenitor cells for cardiovascular
regeneration. Trends Cardiovasc Med. 2008; 18:33-37. [Crossref] 
104. Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, et al. Level and value of 
circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke.
2008; 39:69-74. [Crossref] 
105. Coronel MF, Hernando-Insua A, Rodriguez JM, Elias F, Chasseing NA, Montaner
AD, et al. Oligonucleotide IMT504 reduces neuropathic pain after peripheral nerve
injury. Neurosci Lett. 2008; 444:69-73. [Crossref] 
106. Guo W, Wang H, Zou S, Gu M, Watanabe M, Wei F, et al. Bone marrow stromal cells 
produce long-term pain relief in rat models of persistent pain. Stem Cells. 2011;
29:1294-1303. [Crossref] 
107. Siniscalco D, Giordano C, Galderisi U, Luongo L, de Novellis V, Rossi F, et al. Long- 
lasting effects of human mesenchymal stem cell systemic administration on pain-like 
behaviors, cellular, and biomolecular modifications in neuropathic mice. Front Integr
Neurosci. 2011; 5:79. [Crossref] 
108. Musolino PL, Coronel MF, Hokfelt T and Villar MJ. Bone marrow stromal cells
induce changes in pain behavior after sciatic nerve constriction. Neurosci Lett. 2007;
418:97-101. [Crossref] 
109. Chen G, Park CK, Xie RG and Ji RR. Intrathecal bone marrow stromal cells inhibit
neuropathic pain via TGF-beta secretion. J Clin Invest. 2015; 125:3226-3240.
[Crossref] 
110. Klass M, Gavrikov V, Drury D, Stewart B, Hunter S, Denson DD, et al. Intravenous
mononuclear marrow cells reverse neuropathic pain from experimental
mononeuropathy. Anesth Analg. 2007; 104:944-948. [Crossref] 
111. Naruse K, Sato J, Funakubo M, Hata M, Nakamura N, Kobayashi Y, et al.
Transplantation of bone marrow-derived mononuclear cells improves mechanical
hyperalgesia, cold allodynia and nerve function in diabetic neuropathy. PLoS One.
2011; 6:e27458. [Crossref] 
112. Kondo M, Kamiya H, Himeno T, Naruse K, Nakashima E, Watarai A, et al.
Therapeutic efficacy of bone marrow-derived mononuclear cells in diabetic
polyneuropathy is impaired with aging or diabetes. J Diabetes Investig. 2015; 6:140- 
149. [Crossref] 
113. Usach V, Malet M, Lopez M, Lavalle L, Pinero G, Saccoliti M, et al. Systemic
Transplantation of Bone Marrow Mononuclear Cells Promotes Axonal Regeneration
and Analgesia in a Model of Wallerian Degeneration. Transplantation. 2017;
101:1573-1586. [Crossref] 
114. Huh Y, Ji RR and Chen G. Neuroinflammation, Bone Marrow Stem Cells, and
Chronic Pain. Front Immunol. 2017; 8:1014. [Crossref] 
115. Cuevas P, Carceller F, Dujovny M, Garcia-Gomez I, Cuevas B, Gonzalez- Corrochano 
R, et al. Peripheral nerve regeneration by bone marrow stromal cells. Neurol Res.
Vanina U, Florencia, Mariana M, Gonzalo P, Candelaria L, Mailín C, Marcelo V, Patricia SA, Pablo B. Bone Marrow-Derived Cells and Peripheral Nerve 
Injury-Translational Implications for Pain and Regeneration Treatments Clin Pharmacol Transl Med. 2018; 2(2): 112-124.
Clin Pharmacol Transl Med, 2018 Volume 2(2): 123 - 124 
2002; 24:634-638. [Crossref] 
116. hen CJ, Ou YC, Liao SL, Chen WY, Chen SY, Wu CW, et al. Transplantation of
bone marrow stromal cells for peripheral nerve repair. Exp Neurol. 2007; 204:443- 
453. [Crossref] 
117. Siemionow M, Duggan W, Brzezicki G, Klimczak A, Grykien C, Gatherwright J, et
al. Peripheral nerve defect repair with epineural tubes supported with bone marrow
stromal cells: a preliminary report. Ann Plast Surg. 2011; 67:73-84. [Crossref] 
118. Mohammadi R, Azizi S, Delirezh N, Hobbenaghi R, Amini K, Malekkhetabi P, et al. 
The use of undifferentiated bone marrow stromal cells for sciatic nerve regeneration
in rats. Int J Oral Maxillofac Surg. 2012; 41:650-656. [Crossref] 
119. Mohammadi R, Vahabzadeh B and Amini K. Sciatic nerve regeneration induced by
transplantation of in vitro bone marrow stromal cells into an inside-out artery graft in
rat. J Craniomaxillofac Surg. 2014; 42:1389-1396. [Crossref] 
120. Zhu L, Liu T, Cai J, Ma J and Chen AM. Repair and regeneration of lumbosacral
nerve defects in rats with chitosan conduits containing bone marrow mesenchymal 
stem cells. Injury. 2015; 46:2156-2163. [Crossref] 
121. Yao M, Zhou Y, Xue C, Ren H, Wang S, Zhu H, et al. Repair of Rat Sciatic Nerve
Defects by Using Allogeneic Bone Marrow Mononuclear Cells Combined With
Chitosan/Silk Fibroin Scaffold. Cell Transplant. 2016; 25:983-993. [Crossref] 
122. Wang Y, Jia H, Li WY, Tong XJ, Liu GB, Kang SW, et al. Synergistic effects of
bone mesenchymal stem cells and chondroitinase ABC on nerve regeneration after
acellular nerve allograft in rats. Cell Mol Neurobiol. 2012; 32:361-371. [Crossref] 
123. Wang Y, Jia H, Li WY, Guan LX, Deng L, Liu YC, et al. Molecular examination of
bone marrow stromal cells and chondroitinase ABC-assisted acellular nerve allograft
for peripheral nerve regeneration. Exp Ther Med. 2016; 12:1980-1992. [Crossref] 
124. Goel RK, Suri V, Suri A, Sarkar C, Mohanty S, Sharma MC, et al. Effect of bone
marrow-derived mononuclear cells on nerve regeneration in the transection model of
the rat sciatic nerve. J Clin Neurosci. 2009; 16:1211-1217. [Crossref] 
125. Raheja A, Suri V, Suri A, Sarkar C, Srivastava A, Mohanty S, et al. Dose-dependent 
facilitation of peripheral nerve regeneration by bone marrow-derived mononuclear
cells: a randomized controlled study: laboratory investigation. J Neurosurg. 2012;
117:1170-1181. [Crossref] 
126. Leal MM, Costa-Ferro ZS, Souza BS, Azevedo CM, Carvalho TM, Kaneto CM, et al.
Early transplantation of bone marrow mononuclear cells promotes neuroprotection
and modulation of inflammation after status epilepticus in mice by paracrine
mechanisms. Neurochem Res. 2014; 39:259-268. [Crossref] 
127. Lopes-Filho JD, Caldas HC, Santos FC, Mazzer N, Simoes GF, Kawasaki-Oyama 
RS, et al. Microscopic evidences that bone marrow mononuclear cell treatment
improves sciatic nerve regeneration after neurorrhaphy. Microsc Res Tech. 2011;
74:355-363. [Crossref] 
128. Kurwale NS, Suri V, Srivastava A, Suri A, Mohanti S, Yadav P, et al. Role of bone
marrow derived pluripotent stem cells in peripheral nerve repair in adult rats: A
morphometric evaluation. J Neurosci Rural Pract. 2015; 6:152-159. [Crossref] 
129. Usach V, Goitia B, Lavalle L, Martinez Vivot R and Setton-Avruj P. Bone marrow
mononuclear cells migrate to the demyelinated sciatic nerve and transdifferentiate
into Schwann cells after nerve injury: attempt at a peripheral nervous system intrinsic 
repair mechanism. J Neurosci Res. 2011; 89:1203-1217. [Crossref] 
130. Coronel MF, Musolino PL and Villar MJ. Selective migration and engraftment of
bone marrow mesenchymal stem cells in rat lumbar dorsal root ganglia after sciatic
nerve constriction. Neurosci Lett. 2006; 405:5-9. [Crossref] 
131. Coronel MF, Musolino PL, Brumovsky PR, Hökfelt T and Villar MJ. Bone marrow
stromal cells attenuate injury-induced changes in galanin, NPY and NPY Y1- 
receptor expression after a sciatic nerve constriction. Neuropeptides. 2009; 43:125- 
132. [Crossref] 
132. Wang L, Li Y, Chen X, Chen J, Gautam SC, Xu Y, et al. MCP-1, MIP-1, IL-8 and
ischemic cerebral tissue enhance human bone marrow stromal cell migration in
interface culture. Hematology. 2002; 7:113-117. [Crossref] 
133. Wang L, Li Y, Chen J, Gautam SC, Zhang Z, Lu M, et al. Ischemic cerebral tissue
and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Exp 
Hematol. 2002; 30:831-836. [Crossref] 
134. Ji JF, He BP, Dheen ST and Tay SS. Interactions of chemokines and chemokine
receptors mediate the migration of mesenchymal stem cells to the impaired site in the
brain after hypoglossal nerve injury. Stem Cells. 2004; 22:415-427. [Crossref] 
135. Gleichmann M, Gillen C, Czardybon M, Bosse F, Greiner-Petter R, Auer J, et al.
Cloning and characterization of SDF-1gamma, a novel SDF-1 chemokine transcript
with developmentally regulated expression in the nervous system. Eur J Neurosci.
2000; 12:1857-1866. [Crossref] 
136. White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, et al. Excitatory monocyte
chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic
compression of the dorsal root ganglion. Proc Natl Acad Sci USA. 2005; 102:14092- 
14097. [Crossref] 
137. Soares S, Traka M, von Boxberg Y, Bouquet C, Karagogeos D, Nothias F, et al.
Neuronal and glial expression of the adhesion molecule TAG-1 is regulated after 
peripheral nerve  lesion  or  central  neurodegeneration  of  adult  nervous  system.  
Eur J Neurosci. 2005; 21:1169-1180. [Crossref] 
138. Hiroi S, Tsukamoto Y, Sasaki F, Miki N and Taira E. Involvement of gicerin, a cell
adhesion molecule, in development and regeneration of chick sciatic nerve. FEBS
Lett. 2003; 554:311-314. [Crossref] 
139. Itoh K, Ozaki M, Stevens B and Fields RD. Activity-dependent regulation of N- 
cadherin in DRG neurons: differential regulation of N-cadherin, NCAM, and L1 by
distinct patterns of action potentials. J Neurobiol. 1997; 33:735-748. [Crossref] 
140. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, et al.
Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol.
2000; 164:247-256. [Crossref] 
141. Mezey E and Chandross KJ. Bone marrow: a possible alternative source of cells in
the adult nervous system. Eur J Pharmacol. 2000; 405:297-302. [Crossref] 
142. 142. Chen X, Wang XD, Chen G, Lin WW, Yao J, Gu XS, et al. Study of in vivo
differentiation of rat bone marrow stromal cells into schwann cell-like cells.
Microsurg. 2006; 26:111-115. [Crossref] 
143. Piñero G, Usach V, Soto P, Monje PV, Setton-Avruj CP. "EGFP transgene: a useful
tool to track transplanted bone marrow mononuclear cell contribution to peripheral
remyelination". Transgenic Research. 2018; 27:135-153. [Crossref] 
144. Garg A, Houlihan DD, Aldridge V, Suresh S, Li KK, King AL, et al. Non-enzymatic 
dissociation of human mesenchymal stromal cells improves chemokine-dependent 
migration and maintains immunosuppressive function. Cytotherapy. 2014; 16:545- 
559. [Crossref] 
145. Prockop DJ. "Stemness" does not explain the repair of many tissues by mesenchymal
stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther. 2007; 82:241-243. 
[Crossref] 
146. Eaves CJ, Cashman JD, Kay RJ, Dougherty GJ, Otsuka T, Gaboury LA, et al.
Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in 
long-term human marrow cultures. II. Analysis of positive and negative regulators
produced by stromal cells within the adherent layer. Blood. 1991; 78:110-117.
[Crossref] 
147. Liu LH, Sun Z, Sun QY, Huang YJ, Man QH, Guo M, et al. [Study on biological
characteristics of cultured rhesus mesenchymal stem cells]. Zhongguo Shi Yan Xue
Ye Xue Za Zhi. 2005; 13:417-421. [Crossref] 
148. Majumdar MK, Thiede MA, Mosca JD, Moorman M and Gerson SL. Phenotypic and 
functional comparison of cultures of marrow-derived mesenchymal stem cells
(MSCs) and stromal cells. J Cell Physiol. 1998; 176:57-66. [Crossref]
149. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP and Gerson SL. Human
marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines
and support long-term hematopoiesis when differentiated toward stromal and
osteogenic lineages. J Hematother Stem Cell Res. 2000; 9:841-848.[Crossref] 
150. McMahon SB, Bennett DL, Priestley JV and Shelton DL. The biological effects of
endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG 
fusion molecule. Nat Med. 1995; 1:774-780. [Crossref] 
151. Boucher TJ and McMahon SB. Neurotrophic factors and neuropathic pain. Curr Opin
Pharmacol. 2001; 1:66-72. [Crossref] 
152. Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, et al. Expression
and structure of the human NGF receptor. Cell. 1986; 47:545-554. [Crossref] 
153. Martin-Zanca D, Oskam R, Mitra G, Copeland T and Barbacid M. Molecular and
biochemical characterization of the human trk proto-oncogene. Mol Cell Biol. 1989;
9:24-33. [Crossref] 
154. Verge VM, Merlio JP, Grondin J, Ernfors P, Persson H, Riopelle RJ, et al.
Colocalization of NGF binding sites, trk mRNA, and low-affinity NGF receptor
mRNA in primary sensory neurons: responses to injury and infusion of NGF. J
Neurosci. 1992; 12:4011-4022. [Crossref] 
155. Anjamrooz SH. CMD kinetics and regenerative medicine. Am J Transl Res. 2016;
8:1615-1624. [Crossref] 
156. Soltan M, Smiler D and Choi JH. Bone marrow: orchestrated cells, cytokines, and
growth factors for bone regeneration. Implant Dent. 2009; 18:132-141. [Crossref] 
157. Kim H, Park JS, Choi YJ, Kim MO, Huh YH, Kim SW, et al. Bone marrow
mononuclear cells have neurovascular tropism and improve diabetic neuropathy.
Stem Cells. 2009; 27:1686-1696. [Crossref] 
158. Liu HX, Brumovsky P, Schmidt R, Brown W, Payza K, Hodzic L, et al. Receptor
subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: 
selective actions via GalR1 and GalR2 receptors. Proc. Natl. Acad. Sci. USA. 2001;
98:9960-9964. [Crossref] 
159. Liu HX and Hökfelt T. The participation of galanin in pain processing at the spinal 
level. Trends Pharmacol Sci. 2002; 23:468-474. [Crossref] 
160. Holmes A, Li Q, Koenig EA, Gold E, Stephenson D, Yang RJ, et al. Phenotypic
assessment of galanin overexpressing and galanin receptor R1 knockout mice in the
tail suspension test for depression-related behavior. Psychopharmacology (Berl).
2005; 178:276-285. [Crossref] 
Vanina U, Florencia, Mariana M, Gonzalo P, Candelaria L, Mailín C, Marcelo V, Patricia SA, Pablo B. Bone Marrow-Derived Cells and Peripheral Nerve 
Injury-Translational Implications for Pain and Regeneration Treatments Clin Pharmacol Transl Med. 2018; 2(2): 112-124.
Clin Pharmacol Transl Med, 2018 Volume 2(2): 124 - 124 
161. Holmes FE, Mahoney SA and Wynick D. Use of genetically engineered
transgenicmice to investigate the role of galanin in the peripheral nervous system
afternjury. Neuropeptides. 2005; 39:191-199. [Crossref] 
162. Wiesenfeld-Hallin Z, Xu XJ, Crawley JN and Hokfelt T. Galanin and spinal
nociceptive mechanisms: recent results from transgenic and knock-out models.
Neuropeptides. 2005; 39:207-210. [Crossref] 
163. Brumovsky P, Shi TS, Landry M, Villar MJ and Hökfelt T. Neuropeptide tyrosine
and pain. Trends Pharmacol Sci. 2007; 28:93-102. [Crossref] 
164. Gibbs JL, Diogenes A and Hargreaves KM. Neuropeptide Y modulates effects of
bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1
and Y2 receptors. Br J Pharmacol. 2007; 150:72-79. [Crossref] 
165. Smith PA, Moran TD, Abdulla F, Tumber KK and Taylor BK. Spinal mechanisms of
NPY analgesia. Peptides. 2007; 28:464-474. [Crossref] 
166. Iismaa TP and Shine J. Galanin and galanin receptors. Results Probl Cell Differ.
1999; 26:257-291. [Crossref] 
167. Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and
pancreatic polypeptide. Regul Pept. 1996; 65:165-174. [Crossref] 
168. Xu IS, Hao JX, Xu XJ, Hokfelt T and Wiesenfeld-Hallin Z. The effect of intrathecal
selective agonists of Y1 and Y2 neuropeptide Y receptors on the flexor reflex in
normal and axotomized rats. Brain Res. 1999; 833: 251-257. [Crossref] 
169. Naveilhan P, Hassani H, Lucas G, Blakeman KH, Hao JX, Xu XJ, et al. Reduced
antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor.
Nature. 2001; 409:513-517. [Crossref] 
170. Moran TD, Colmers WF and Smith PA. Opioid-like actions of neuropeptide Y in rat
substantia gelatinosa: Y1 suppression of inhibition and Y2 suppression of excitation.
J Neurophysiol. 2004; 92:3266-3275. [Crossref] 
171. Taylor BK, Fu W, Kuphal KE, Stiller CO, Winter MK, Chen W, et al. Inflammation
enhances Y1 receptor signaling, neuropeptide Y-mediated inhibition of hyperalgesia,
and substance P release from primary afferent neurons. Neurosci. 2014; 256:178-194. 
[Crossref] 
172. Xu ZQ, Shi TJ, Landry M and Hokfelt T. Evidence for galanin receptors in primary
sensory neurones and effect of axotomy and inflammation. Neuroreport. 1996; 8:237- 
242. [Crossref] 
173. Zhang X, Xu ZO, Shi TJ, Landry M, Holmberg K, Ju G, et al. Regulation of
expression of galanin and galanin receptors in dorsal root ganglia and spinal cord
after axotomy and inflammation. Ann N Y Acad Sci. 1998; 863: 402-413.[Crossref] 
174. Sten Shi TJ, Zhang X, Holmberg K, Xu ZQ and Hokfelt T. Expression and regulation
of galanin-R2 receptors in rat primary sensory neurons: effect of axotomy and
inflammation. Neurosci Lett. 1997; 237:57-60. [Crossref] 
175. Perkins NM and Tracey DJ. Hyperalgesia due to nerve injury: role of neutrophils.
Neuroscience. 2000; 101:745-757. [Crossref] 
176. DeFrancesco-Lisowitz A, Lindborg JA, Niemi JP and Zigmond RE. The
neuroimmunology of degeneration and regeneration in the peripheral nervous
system. Neuroscience. 2015; 302:174-203. [Crossref] 
177. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. 
Neuropathic pain. Nat Rev Dis Primers. 2017; 3:17002. [Crossref] 
178. Mirzaei H, Sahebkar A, Shiri L, Moridikia A, Nazari S, Nahand JS, et al. Therapeutic 
Application of Multipotent Stem Cells. J Cell Physiol. 2017; 9999:1-9.[Crossref] 
179. Mariano ED, Teixeira MJ, Marie SK and Lepski G. Adult stem cells in neural repair: 
Current options, limitations and perspectives. World J Stem Cells. 2015; 7:477-482. 
[Crossref] 
180. Guadix JA, Zugaza JL and Galvez-Martin P. Characteristics, applications and
prospects of mesenchymal stem cells in cell therapy. Med Clin (Barc). 2017;
148:408-414. [Crossref] 
181. Orozco L, Soler R, Morera C, Alberca M, Sanchez A, Garcia-Sancho J, et al.
Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study.
Transplantation. 2011; 92:822-828. [Crossref] 
182. Vega A, Martin-Ferrero MA, Del Canto F, Alberca M, Garcia V, Munar A, et al.
Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem
Cells: A Randomized Controlled Trial. Transplantation. 2015; 99:1681-1690. 
[Crossref] 
183. Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, et al.
Long-term cultures of bone marrow-derived human mesenchymal stem cells
frequently undergo spontaneous malignant transformation. Cancer Res. 2009;
69:5331-5339. [Crossref] 
184. Naito Y, Rocco K, Kurobe H, Maxfield M, Breuer C, Shinoka T, et al. Tissue
engineering in the vasculature. Anat Rec (Hoboken). 2014; 297:83-97.[Crossref] 
185. Taguchi A, Sakai C, Soma T, Kasahara Y, Stern DM, Kajimoto K, et al. Intravenous
Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a
Clinical Trial in a Homogeneous Group of Stroke Patients. Stem Cells Dev. 2015; 24: 
2207-2218. [Crossref] 
186. Giannini S, Buda R, Vannini F, Cavallo M and Grigolo B. One-step bone marrow- 
derived cell transplantation in talar osteochondral lesions. Clin Orthop Relat Res.
2009; 467:3307-3320. [Crossref] 
187. Meluzin J, Mayer J, Groch L, Janousek S, Hornacek I, Hlinomaz O, et al. Autologous 
transplantation of mononuclear bone marrow cells in patients with acute myocardial
infarction: the effect of the dose of transplanted cells on myocardial function. Am
Heart J. 2006; 152: 975.e-975.e15. [Crossref] 
188. Gyongyosi M, Giurgea GA, Syeda B, Charwat S, Marzluf B, Mascherbauer J, et al.
Long-Term Outcome of Combined (Percutaneous Intramyocardial and Intracoronary) 
Application of Autologous Bone Marrow Mononuclear Cells Post Myocardial
Infarction: The 5-Year MYSTAR Study. PLoS One. 2016; 11: e0164908.[Crossref] 
189. Cox CS, Hetz RA, Liao GP, Aertker BM, Ewing-Cobbs L, Juranek J, et al. Treatment 
of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells.
Stem Cells. 2017; 35:1065-1079. [Crossref] 
190. Moniche F, Rosado-de-Castro PH, Escudero I, Zapata E, de la Torre Laviana FJ,
Mendez-Otero R, et al. Increasing Dose of Autologous Bone Marrow Mononuclear 
Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis
of Two Clinical Trials. Stem Cells Int. 2016; 2016: 8657173. [Crossref] 
191. Gabr H, Hedayet A, Imam U and Nasser M. Limb salvage using intramuscular
injection of unfractionated autologous bone marrow mononuclear cells in critical limb 
ischemia: a prospective pilot clinical trial. Exp Clin Transplant. 2011; 9:197- 
202. [Crossref] 
192. Ruiz-Lopez FJ, Guardiola J, Izura V, Gomez-Espuch J, Iniesta F, Blanquer M, et al.
Breathing pattern in a phase I clinical trial of intraspinal injection of autologous bone 
marrow mononuclear cells in patients with amyotrophic lateral sclerosis. Respir
Physiol Neurobiol. 2016; 221:54-58. [Crossref] 
193. Braga-Silva J, Gehlen D, Padoin AV, Machado DC, Garicochea B, Costa da Costa J,
et al. Can local supply of bone marrow mononuclear cells improve the outcome from 
late tubular repair of human median and ulnar nerves? J Hand Surg Eur Vol. 2008;
33:488-493. [Crossref] 
194. Savitz SI, Dinsmore JH, Wechsler LR, Rosenbaum DM and Caplan LR. Cell therapy
for stroke. NeuroRx. 2004; 1:406-414. [Crossref] 
195. Lu D, Li Y, Wang L, Chen J, Mahmood A, Chopp M, et al. Intraarterial
administration of marrow stromal cells in a rat model of traumatic brain injury. J
Neurotrauma. 2001; 18:813-819. [Crossref] 
196. Lu L, Zhao C, Liu Y, Sun X, Duan C, Ji M, et al. Therapeutic benefit of TH- 
engineered mesenchymal stem cells for Parkinson's disease. Brain Res Brain Res
Protoc. 2005; 15:46-51. [Crossref] 
197. Ohta M, Suzuki Y, Noda T, Ejiri Y, Dezawa M, Kataoka K, et al. Bone marrow
stromal cells infused into the cerebrospinal fluid promote functional recovery of the
injured rat spinal cord with reduced cavity formation. Exp Neurol. 2004; 187:266- 
278. [Crossref] 
Vanina U, Florencia, Mariana M, Gonzalo P, Candelaria L, Mailín C, Marcelo V, Patricia SA, Pablo B. Bone Marrow-Derived Cells and Peripheral Nerve 
Injury-Translational Implications for Pain and Regeneration Treatments Clin Pharmacol Transl Med. 2018; 2(2): 112-124.
